ArsenalBio Secures $325M in Series C Funding for Solid Tumor Cell Therapy Trials

Funding:
ArsenalBio, a cell therapy startup, has raised $325 million in a Series C funding round.

Purpose:
The funding will support the development of experimental cancer cell therapies, including trials for ovarian and kidney cancers.

Trials:
The company is currently conducting two early-stage trials for solid tumors.

Significance:
This funding round is one of the largest biotech funding rounds of the year, indicating strong investor interest in cell therapy technologies.